Stellar Biotechnologies

Activities: Research & Development Pharmaceutical

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Recruitment

Stellar Biotechnologies appoints pharma and capital markets experts to board of directors

Stellar Biotechnologies, a leading manufacturer of a key protein utilised in multiple immunotherapy development pipelines targeting cancers, Alzheimer's and lupus, among other diseases, has announced the appointment of Charles V. Olson, DSc and Paul Chun to the company's board of directors
Manufacturing

SAFC signs KLH agreement with Stellar Biotechnologies

Stellar will provide limpet blood produced in a controlled environment for cGMP manufacturing
Research & Development

Stellar receives milestone from Bayer Innovation

The firms will expand their joint development agreement
Subscribe now